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Pulmonary Tuberculosis (PTB) rates in Kwa Zulu Natal (KZN) is amongst the highest in the 
South Africa and is often associated with Human Immunodeficiency Virus (HIV) co-infection.  
Bronchial Artery Embolisation (BAE) is an expensive, time consuming procedure requiring 
operator skill and is accompanied by risk to both patient and operator.   
Aim: 
To investigate the impact of HIV infection when superimposed on PTB (active or sequelae) on 
the success of BAE. 
Method: 
A retrospective cross sectional study with descriptive and analytical components of the BAE 
procedure between January 2006 and December 2007 was performed on sequential BAE studies.  
These were analyzed for procedural and clinical outcome and reasons for procedural failure were 
investigated.  The impact of CD4 level on procedural and clinical failure was investigated for a 
subset of cases. 
Cases were included if they presented with massive or life threatening haemoptysis with a 
diagnosis of previous or active PTB (made clinically, radiologically or microbiologically) in 
whom HIV status is known and where the clinician assessed a need for BAE, but excluded any 






The final sample size after exclusion of 91 cases is 107.  Each attempt at BAE was viewed as an 
individual case.  The study population is made up of 74 HIV positive and 33 HIV negative cases.   
The median CD4 level is 176 cells / microlitre. 
Statistically, procedural success does not imply clinically successful outcome.HIV status does 
not correlate significantly with clinical or procedural results of BAE.CD4 level does not correlate 
significantly with clinical or procedural results of BAE. 
There is no technical reason of statistical significance that impacts on the success of the 
procedure when correlated with HIV status.  These include being unable to select, unable to 
subselect, unable to engage securely, reflux, presence of fistulae and the presence of spinal 
feeder arteries. 
The complication rate is not statistically significant when correlated with HIV status.  The 
differences in follow up of clinically unsuccessful cases were not significant when correlated 
with HIV status. 
On imaging, all cases demonstrated pathology. No particular zone is significant when correlated 
with HIV status.  The most common finding is parenchymal architectural distortion followed 
closely by features of active tuberculous infection and no statistical significance is attributed to 
either when correlated with HIV status.  The detection of lymphadenopathy is noted in 19.1% of 
HIV positive cases and 42.4% of HIV negative cases, and is the only feature of significance 





Coinfection with HIV does not have an impact on the success of BAE in patients with active or 
sequelae PTB who present with massive or life threatening haemoptysis. 
The rate of technical failure of the procedure suggests that this needs to be performed by persons 
that are adequately trained. Technical success does not imply clinical success but this finding 
was not statistically significant when correlated with HIV status.  Re-evaluation of the procedure 















CHAPTER 1: INTRODUCTION 
The literature is extensive on the topic of Bronchial Artery Embolisation (BAE) and its efficacy 
as a means of treatment and palliation of haemoptysis.   There is agreement that BAE is a safe 
and effective method of management and palliation of haemoptysis.  Immediate success rates of 
the procedure range from 73% by Ramakantan et al in 1996 to 99% by Lee et al in 2008(1, 2).  
Not all studies have described technical failure and reasons for this.  Annexure 1 summarizes 
details of the studies in the literature including case numbers, reasons for technical failure, 
etiology of haemoptysis, clinical presentation and whether HIV status was investigated.   
 
1.1 Demographics data related to Pulmonary Tuberculosis (PTB) and Human                                     
Immunodeficiency  Virus infection (HIV) 
By the end of 2007 the province of KwaZulu Natal (KZN) had a population of 10 014 500 
accounting for 20.9% of the population of South Africa(3).  The province consists of 54% rural 
settlements and has 8.6% of the population living in informal homes(3). 
The number of new cases of pulmonary tuberculosis (PTB) rose from 2006 to 2007 from 88271 
to 93204, with an increase of new PTB cases from 37 - 40%  (new smear positive 337.6/100000 
to 372.7/100 000 people) in that period(3). This incidence is third highest in the country after the 
Northern and Western Cape (4). 
The cure rate of new smear positive cases of PTB for KZN remained the lowest in the country at 
45.2% and 52.9% in 2005 and 2007 respectively, with the highest death rate in the country in 
2005 of 236 persons per 100 000(3).   
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In 2007, the number of people living with Human Immunodeficiency Virus (HIV) infection in 
the province was 1 552 390(3).  The most common cause of death (57.5%) in the country was 
Acquired Immune Deficiency Syndrome (AIDS) and the HIV incidence (new cases per year as a 
percentage of the uninfected population) is the highest in the country at 1.6% of total deaths(3).  
In 2006, 7.7% of new global cases of PTB were co-infected with HIV and this rose to 14.8%  in 
2007(5, 6).  The epicenter of the co-epidemic lay in southern Africa (79%) (6).  South Africa had 
the second highest incidence of PTB and HIV infection (following Swaziland) in 2006 and 2007 
(5, 6).  Figure 1 demonstrates the worldwide distribution of HIV-PTB co-infection in 2007. 
 
Figure 1:  Worldwide distribution of HIV-PTB coinfection shown as a percentage of the global 
total in 2007.  ‘AFR represents all countries in the WHO African region other than those shown 
separately.  AMR represents all countries in the WHO region of the Americas except Brazil.  
EUR is the WHO European region excluding the Russian Federation.  SEAR is the WHO south-




1.2 Bronchial Artery Embolisation (BAE) at Inkosi Albert Luthuli Central Hospital 
(IALCH) 
Inkosi Albert Luthuli Central Hospital in Durban has the only public sector Cardiothoracic Unit 
in the province of KZN and serves as the specialist referral centre for this province and the 
Eastern Cape as far south as Umtata.  The Department presently deals with all types of 
cardiothoracic surgery other than transplantation.  It is an 846 bed hospital with 92 beds afforded 
to the Cardiothoracic Unit (including paediatric cardiothoracic beds).  In 2006 and 2007 the unit 
had 1379 and 1392 admissions respectively.  In 2006 and 2007, 15 and 28 pneumonectomies and 
42 and 41 lobectomies respectively, were performed for a diagnosis of bronchiectasis.  The vast 
majority of these cases were on the basis of old pulmonary tuberculosis. 
The most common presentation of PTB is haemoptysis and patients presenting with haemoptysis 
is common at Durban hospitals.  Massive haemoptysis is associated with a mortality rate ranging 
from 30 - 50% (7).  In the late 1960s emergency lung resection assisted in reducing the mortality 
rate, but the overall mortality, especially after emergency surgery as opposed to elective surgery 
is still high and ranges from 10-38% (7, 8).  It has therefore been the role of Bronchial Artery 
Embolisation (BAE) to temporize the bleeding until elective surgery can be planned while 







1.3 Definition of Massive Haemoptysis 
The definition of massive haemoptysis is controversial.  Quantitatively it has been defined as 
expectoration of blood of 100 to 1000mls per 24 hours.  The most widely used criterion is the 
expectoration of 300 to 600mls per 24 hours (9).  It is estimated that more than 400mls of blood 
in the alveolar spaces is sufficient to cause impairment of oxygenation (10) and leads to the 
morbidity of the patient by asphyxiation rather than exanguination (8) .  Observed quantitative 
expectoration may underestimate the actual volume of blood loss should it remain in the alveoli 
and expectoration of even a small amount of blood in a person with impaired pulmonary 
function, such as Chronic Obstructive Airways Disease (COAD) or Congestive Cardiac Failure 
(CCF), can lead to a life threatening state.  Therefore, the definition should include a functional 
assessment of the effect of the haemoptysis (9).   
For the purposes of this study, massive haemoptysis is defined as the expectoration of 300 to 
600mls of blood per 24 hours; or less if the result is life threatening and/or required blood 
transfusion for significant reduction in hemoglobin level; and is not controllable by conservative 
measures as regarded by the clinician in charge of the patient. 
 
1.4 Aetiology of Massive Haemoptysis 
While the etiology of massive haemoptysis in the western world is extensive (led by 
bronchiectasis caused by Cystic Fibrosis and carcinoma of the bronchus), the most common 
etiology in sub Saharan Africa is secondary to pulmonary tuberculosis or the sequelae of 
previous PTB infection such as bronchiectasis (7) followed by bronchogenic carcinoma(5%) (7). 
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In the developed world one must consider aspergillosis, lung abscess, bronchiectasis, carcinoma, 
cystic fibrosis, pneumonia, pulmonary interstitial fibrosis, pneumoconiosis, congenital cardiac 
and vascular abnormalities, aorto-bronchial fistula, aortic aneurysm, bronchial artery aneurysm 
or pulmonary artery aneurysm (11). 
 
1.5 Pathophysiology of Pulmonary Tuberculosis 
The lungs are the primary site of infection of the bacillus Mycobacterium Tuberculosis (MTB), 
an airborne acid-fast bacteria that is latent in lung parenchyma of all those exposed to it. The 
disease process manifests when the patient mounts an immune response, leading to clinical 
symptoms and signs.  
Haemoptysis results from embarrassment of the bronchial arteries (consequent to structural 
alterations in the caliber and integrity of the vessels) in most cases (90%), although 
embarrassment of other vessels such as the pulmonary arteries (5%)  or systemic vessels have 
been documented as well (9, 11, 12).   
Following acute or chronic lung condition, hypoxic vasoconstriction, intravascular thrombosis 
and vasculitis (13) bronchial artery proliferation occurs (9) as a compensatory mechanism.  
These are seen angiographically as bronchial arteries larger than1-2mm in diameter (9).  
Neovascularity promotes aberrant vasculopathy in terms of arterial-arterial and arterial-venous 
fistulation.  Bronchopulmonary shunts develop within peribronchial inflammatory tissue (9) also 
contributing to the increase in size of the bronchial and other collateral arteries (9) because of 
increased blood flow.  These enlarged vessels exist in a region of inflammation (acute/chronic) 
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and may rupture following erosion by bacterial agents or due to exposure to elevated blood 
pressure (9, 13), and results in extravasation into the bronchoalveolar tree.   
Residual damage leads to bronchiectasis, broncholith formation or allows for the formation of an 
intracavitary mycetoma.  These factors contribute to bleeding from the bronchial arteries.  In 
bronchiectasis the hypertrophied bronchial arteries, being systemic arteries, are subject to the 
systemic arterial pressure and this leads to massive haemoptysis.  The most common cause 
(73%) of bronchiectasis documented in the Western Cape is post tuberculous changes (7). 
In treated PTB, residual scarring and cavitation contributes to the fragility of the vessels 
supplying these regions (9).  Other mechanisms of haemoptysis include the formation and 
rupture of a Rasmussen’s aneurysm caused by the erosion of pulmonary artery. Therefore 
massive haemoptysis can be a presentation of active or treated sequelae of PTB. 
Embolisation of the bronchial arteries aims to decrease the perfusion pressure to fragile vessels 
by occluding the arteries, staunching the vascular compromise and decreasing the likelihood of 
alveolar flooding and haemoptysis (9).  Embolisation should be done close to the abnormality to 
prevent establishment of non-bronchial systemic collateral vessels later (9). 
In order to defend the body against intracellular growth of MTB, Cluster of Differentiation 4 
cells (CD4) produce a number of immunological factors and it is the reduction of these factors in 
HIV infection that leads to a increased risk of developing reactivation or reinfection (14).  In 
addition, the tuberculous granuloma has been associated with an increased HIV viraemia with 
the risk of death in HIV infected patients with TB doubling that of HIV infection patients 
without TB with matched CD4 cell counts (15).  HIV arteritis would result in inflammation of 
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the media of the vessel rendering it unstable and more susceptible to the high pressures of the 
systemic circulation and therefore, more easily incompetent. 
 
1.6  Diagnosis of Pulmonary Tuberculosis 
The diagnosis of PTB is confirmed by the presence of acid-fast bacilli (AFB) on smear or a 
positive culture of MTB of sputum sample, histological evidence of granuloma responding to 
appropriate antituberculous treatment or an anatomical diagnosis of tuberculosis at necropsy 
(16).   
In the presence of concurrent HIV infection a higher false negative rate of sputum smears has 
been found.   The literature is contradictory with regards to the confidence interval of sputum 
positivity rates and culture proven MTB.  Smith et al reported that positive acid fast sputum 
smears in culture proven MTB occur with similar frequency in patients with and without HIV 
(84 versus 85%) (17) compared with Klein et al who showed a decreased sensitivity of sputum 
positive smears in culture positive MTB among patients with HIV infection (45 versus 81 
percent among patients without HIV)(18). 
For patients with HIV, the likelihood of a positive smear was also found to be independent of 
CD4 counts and drug resistance and Smith et al quotes 58 vs 50% for HIV positive and HIV 
negative patients (17) 
In a South African study, the yield of positive culture on the first sputum sample was 74% on 
smear negative patients and 86% on smear positive patients.  Examination of multiple sputum 
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smears produces a higher cumulative yield in HIV-associated tuberculosis suggesting a potential 
delay in diagnosis. (16). 
In our environment because of the high rate of PTB infection our clincians are suspicious of PTB 
infection in any patient presenting with haemoptysis and often treatment is institued before 
positive culture has been established.  Correlation with clinical and radiographic findings is 
performed acutely and management decisions were made before sputum is sent for microscopy 
and culture.  The laboratory diagnosed PTB infection was confirmed retrospectively. 
 
1.7 Pulmonary Tuberculosis in HIV Positive Patients 
There are recognizable differences in presentation, extent and severity of PTB when HIV 
infection co-exists.  HIV and PTB share the same exacerbating factors and TB has been shown to 
speed the progression of HIV infection to AIDS in dually affected individuals and significantly 
reduce survival rate (19) even when other risk factors are taken into consideration.  In particular 
localized parenchymal PTB disease was less commonly seen in HIV positive patients and there 
is a higher prevalence of disseminated disease (14), military disease, lymphadenopathy, extra-
pulmonary disease and features of primary tuberculosis when the patient become more 
immunocompromised (10, 20, 21). 
A local study of HIV seroconverter cohort of gold miners found that TB risk rapidly increased 





1.8 Radiological Findings  
1.8.1 Chest Radiograph and HRCT Chest 
1.8.1.1  Role of imaging and modalities 
The diagnostic workup aims to locate and establish the cause of the bleeding in order to plan 
purposeful embolisation of the affected bronchial arteries.  Bronchoscopy is a useful diagnostic 
and therapeutic modality but one needs to be aware of the timing and limitations of the 
procedure. 
Chest radiographs (CXR) are routinely performed on patients with a presentation of 
haemoptysis.  While it is widely available there is a wide range of radiographic appearances of 
the different stages of pulmonary tuberculosis on CXR including a large proportion of normal 
radiographs.  In a retrospective study of 208 patients with haemoptysis, the CXR was found to be 
diagnositic in only 50% of cases (23).  The CXR may fail to localise a lesion because the chest 
radiograph is either normal or shows bilateral disease (4).  In the presence of concurrent HIV 
infection, higher rates of false negative CXR are noted (10, 14). 
Computed Tomography of the Chest (CT Chest) is more helpful than CXR in excluding other 
causes of haemoptysis.  CT chest, if used alone, is the most sensitive diagnostic test with a 
positive yield of 67% (23) and can suggest a specific diagnosis.  It is often used to detect lesions 
overlooked on standard radiographs, to define equivocal lesions or to analyse complications (24).  
High Resolution Computed Tomography (HRCT) of the chest, by virtue of its thin slice width, is 
helpful in differentiating active from inactive disease.  It is also more sensitive to the detection of 
miliary spread of infection, detection of small cavities, differentiation of paracicatricial 
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emphysema from bronchiectasis and cavities (24) and assessement of lymphadenopathy.  CT 
Chest or HRCT chest is sensitive to the detection of aspergillomas (aspergillous infection found 
in mycetomas) which has been established to be a risk factor for recurrence of haemoptysis 
following bronchial artery embolisation (25-27).   
Contrast Enhanced CT Scan can be used to detect alternate vascular etiology and may help 
visualize the bronchial and non bronchial systemic feeder vessels.  
 
1.8.1.2  Features of  Pulmonary Tuberculosis on imaging 
Primary PTB in an adult in South Africa is considered rare due to the high disease prevalence at 
a young age and routine immunisation with Bacille Calmette-Guerin vaccine at birth.  Typical 
appearances of primary PTB are airspace consolidation predominately in the lower lobes, 
lymphadenopathy, pleural effusion and miliary disease (28).  
Post primary pulmonary tuberculosis occurs with reactivation of dormant bacilli, often during 
periods of immunosuppression, malnutrition and debilitation or as the result of aging (24).  Post 
primary TB is chronic and slowly progressive compared with primary PTB where fibrosis and 
healing is more the norm (28).  While features of previous primary disease may be present, the 
commoner appearance of active disease is the presence of a secondary focus or tuberculoma in 
the apical and posterior segments of the upper lobes or the superior segment of the lower lobe.  
This may be infiltrative or consolidative with or without cavitation or nodules.  Cavitation is the 
hallmark of post primary TB (24).  Endobronchial spread may occur in the absence of cavitation 
and presents radiographically as ‘tree in bud’ appearance.  Acinar (peribronchiolar) nodules 
suggests bronchogenic dissemination and even in the appropriate clinical setting has a wide 
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differential diagnosis.  Miliary nodules are micronodules spread evenly in the lung parenchymal 
without any zonal or lobular predominance but this appearance is more commonly seen in 
immunocompetent patient who have primary PTB (20).  
Kim et al have categoried features of previous and inactive disease as ‘parenchymal, airway, 
vascular, mediastinal, pleural and extrapleural changes’.  Parenchymal features of 
fibroarchitectural distortion manifests as fibrotic bands, calcified nodules, atelectasis, 
cicatrization and end stage lung destruction. Destruction of lung can follow progressive primary 
infection, prolonged cavitation, reinfection, spread and fibrosis (24) and complete destruction of 
lung is not uncommon as a result of parenchymal and airway involvment (28).  Once there is 
destruction of lung parenchyma, assessment of new disease activity is challenging.  
Airway manifestations include bronchiectasis, broncholithiasis and tracheobronchial 
stenosis(28).  Bronchiectasis may be the consequence of TB involvement of the bronchial wall 
and subsequent fibrosis namely cicatrical bronchial stenosis, or more commonly, destruction and 
fibrosis of lung parenchyma with secondary bronchial dilatation namely traction bronchiectasis 
(28).  When bronchiectasis is seen in the apical and or posterior upper lobe this is suggestive of 
TB being the primary aetiology (28).  Tracheobronchial stenosis is the result of granulomatous 
changes in the wall or from extrinsic pressure from enlarged peribronchial lymph nodes(28).  
Vascular manifestations include pulmonary or bronchial artery arteritis or thrombosis in an area 
of active infection, bronchial artery dilatation and, less commonly, Rasmussen aneurysm 
formation(28).  Bronchial artery dilatation may accompany parenchymal PTB or be associated 
with PTB bronchiectasis.  Other manifestation on imaging include calcified lymphadenopathy, 
fibrosing mediastinitis, empyema, fibrothorax, bronchopleural fistula and pneumothorax (28).  
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With concurrent HIV infection, the manifestation and diagnosis of PTB on imaging becomes 
more complicated.  As the disease course depends on the host immune response to the organism 
virulence, the manifestations are often less severe.  The sensitivity of CXR to screen for PTB 
decreases with normal radiographs having been reported in up to 40% of sputum positive 
cultures (10) as opposed to 15% in HIV seronegative patients. In seropositive patients there is a 
lower prevalence of parenchymal consolidation, cavitation and post primary pattern, and a higher 
prevalence of extrapulmonary and miliary disease as compared with seronegative patients (14, 
24). The sensitivity of CT scan to detect PTB remained independent of HIV status (14).  
 
1.8.2 Bronchial Artery Embolisation 
1.8.2.1  Role of the procedure 
BAE was first performed in 1973 by Remy et al (11). Today, it usually utilizes Digital 
Subtraction Angiography Technique for its superior spatial resolution, rapid acquisition and 
review capabilities (9).  A transfemoral approach is used to select and embolise the bronchial 
arteries.   
Bleeding originates from the bronchial arteries in the majority of patients (15).  Even mild 
bleeding originating from the bronchial arteries can cause life-threateing hemotpysis due to the 
higher blood pressure (15) in these vessels.  Since then, sub-selection and super selection has 
allowed embolisation of the artery as close to the site of haemorrhage as possible by bypassing 
areas that would previously have precluded safe embolisation(9).   
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Non-exhaustive BAE in the acute setting refers to embolisation of the bronchial arteries only.  
However, it has been shown that early (within 2 weeks) failure rate of the procedure could be 
accounted for by an incomplete procedure where the other systemic arteries (such as the internal 
mammary artery or the phrenic artery) that maybe involved in haemorrhage are not embolised 
(29).  Nevertheless, BAE has been shown to achieve high rates of immediate control of 
haemoptysis and is generally accepted as a first line treatment for acute massive haemoptysis.  
The literature quotes immediate response rates from 73 to 98% (2, 9, 11, 12, 30, 31).  With the 
advent of coaxial microcatheter expertise and availability, the ability to achieve immediate 
control of haemoptysis approaches 90% (25) to 95.7% (29) with reduction of observed 
complications (2). 
Some centers promote emergency surgery as initial management especially if the bleeding point 
is localized and pulmonary function test permits pulmonary resection, because it permits 
definitive treatment of haemoptysis by removing the source of bleeding  (26, 30, 31).  When 
active PTB is the cause, surgery can be deferred in the emergency setting with BAE used to 
control haemoptysis until such time as effective medical treatment can be initiated and sustained.  
Traditionally surgery during active infection, before the initiation and maintenance on medical 
treatment, has been associated with a poor surgical and clinical outcome as a result of higher 
complication rates (7). 
 
1.8.2.2 Technique and Complications  
The literature documents many complications of the procedure.  These include, amongst others, 
contrast reaction, subsequent renal function impairment, introduction of infection, procedural 
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complications such as puncture site thrombosis, subintimal dissection of femoral, aorta or 
bronchial arteries, fistulation, haemorrhage or puncture site haematoma formation and femoral 
nerve damage(9).  
Complications of embolisation itself include transverse-myelitis (9, 31) (less common now as a 
result of lower osmolar contrast media), bronchial or aortic necrosis, inappropriate embolisation 
of non target tissue such as the colon, pulmonary infarction, ipsilateral face and orbital pain and 
transient cortical blindness, extremities, complication of catheterization or disturbance of ostia of 
other vessels, embolism, dissection and clinically evident complications such as transient chest 
pain, transient dysphagia, and broncho-oesophageal fistula. 
For the radiologist the risks of the procedure includes exposure to blood, blood products and 
blood borne infection such as HIV and hepatitis, needle stick injury risk and radiation exposure. 
Technical failure of the procedure may be broadly accounted for by failed bronchial arterial 
access or the presence of contraindications to embolisation.   
Failed bronchial access may be due to differing level of skill and experience of the operator, 
inability to cannulate artery (dependant on size of vessel, take off from parent vessel), variant 
anatomy; or distorted anatomy from previous intervention or end stage lung disease from 
previous disease.  In 70% of people the origin of the bronchial arteries is found to arise between 
the top of the fifth thoracic vertebrae and  the bottom of the sixth thoracic vertebrae (9).  
Variations of this include the vessels arising from the aortic arch or from visceral vessels such as 
the internal mammary artery, thyrocervical trunk or inferior phrenic artery (32).  Most 
commonly, there are 2 left bronchial arteries and 1 right bronchial artery, followed by bilateral 
single bronchial arteries, all of which emerge anterolaterally from the aorta. The right 
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intercostobronchial trunk is the most common vessel identified and is seen in 80% of patients 
(9). 
Contraindications to safe embolisation include failure to securely cannulate the pathological 
vessel (31) resulting in dislodgement and inadvertent embolisation of non target tissue.  This 
may be prevented by screening the tip of the catheter at all times during embolisation. 
The presence of reflux during embolisation can be appreciated on a magnified view of the 
catheter tip during continuous screening. It appears as a blush of contrast in the aorta and is 
usually the result of poor engagement of the vessel.  Detection of reflux is optimized by mixing 
embolic material with concentrated contrast.  Reflux contraindicates embolisation with 
embospheres as it results in distal non-target embolisation. Better engagement with 
microcatheters or change in catheter is advised.  Watching for reflux during the entire 
embolisation procedure is mandatory as it may only become evident when the pathological 
vessel, having been partially embolised, experiences slower flow due to an increase in distal 
resistance. 
Inappropriate non-target embolisation may also result from not flushing the catheter with saline 
prior to disengagement, before or after selection of another vessel. 
An important complication to be aware of is embolisation of a spinal arterial feeder resulting in 
spinal cord ischemia or infarction.  Spinal arteries may be evident at the start of embolisation or 
become more easily detected following partial embolisation when the steal phenomenon of the 
pathological bronchial arteries is being staunched. When a spinal arterial feeder is identified one 
should attempt to subselect or superselect beyond its origin using a coaxial system and avoid 
forceful embolisation to prevent reflux into the spinal feeder (9).   
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It has been reported that it is uncommon for spinal arteries to arise from a bronchial artery (9) but 
in view of the complications associated with spinal artery embolisation, one should look for 
these carefully. There are many small branches seen to arise from the right intercostobronchial 
trunk and course towards the midline but their supply to the spinal cord should be confirmed on a 
lateral view (9).  Another common site of origin of spinal vessels is from the right fifth 
intercostal artery and therefore care must be taken when an exhaustive embolisation of other 
systemic vessels is undertaken.  Embolisation into the fifth right intercostal artery with ionic 
contrast media has been reported to be a risk for transverse myelitis (33, 34).  
The most concerning spinal artery is that of the anterior spinal artery of Adamkiewitz. This arises 
between the ninth and twelfth thoracic vertebrae in 75% of cases (13) and has a characteristic 
hairpin bend seen on the subtracted anteroposterior (AP) view.  This should be confirmed on a 
steep oblique or lateral view and viewed on the native image.   
A fistula is a direct communication between two endothelial surfaces.  Embolisation through 
bronchopulmonary anastomosis can result in pulmonary infarction (via pulmonary arterial 
embolisation) or systemic organ infarction (via pulmonary vein embolisation) (9).  The 
consequence of embolisation in the presence of a pulmonary–bronchial artery fistula depends on 
the size of embolic material and how proximal the fistula is in relation to the pulmonary artery, 
the most significant of which is embolisation of the entire lung.  We use a delay in appearance of 
the pulmonary vein to decide if there is an adequate pulmonary bed present.  Arterial-arterial 
fistula is found between the bronchial artery and visceral arteries such as the subclavian artery, 
cervical trunk vessels or the vertebral artery.  To prevent non-target embolisation one must sub- 
select beyond the fistulous region prior to embolisation.   
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Post-embolisation syndrome can last for 5 to 7 days, is characterized by pleuritic pain, fever, 
dysphagia and leukocytosis and responds to symptomatic treatment (35). 
Signs on arteriography that suggests site of bleeding include enlargement of vessel, vascular 
blush, increase in hypervascularity and evidence of vascular shunts between the systemic arteries 
and pulmonary artery and vein.  This may be pronounced enough to demonstrate reversal of flow 
in the pulmonary arteries (9).  The pan-aortogram allows for visualisation of non-bronchial 
collateral vessels that may also need to be embolised.  Abnormal vascularity shown 
angiographically has no correlation with the degree of hemoptysis (9) and too forceful injection 
of contrast can produce a similar hypervascular angiographic appearance (9).  Nevertheless, non 
visualisation of hypertrophied bronchial arteries on pan-aortogram should not stop one from 
attempting to cannulate the bronchial arteries, as bleeding may occur from vessels that are 
normal in size(9). 
There are a variety of methods available to embolise the vessels and the most commonly used 
agent is polyvinyl alcohol (PVA).  These are available in various sizes but sizes of 350-500 
micrometers in diameter are recommended (13) because these are large enough to embolise the 
target vessel distally but are not small enough to allow for occlusion of the pulmonary capillary 
bed, oesophageal vessels,  vasavasorum of the pulmonary artery or aorta (9), or pass through 
bronchopulmonary anastomosis (13).   
Other agents include absorbable gelatin sponge or the use of coils.  Neither of these is 
recommended as sole therapy because of the likelihood of recanalization in the former and 
diminished accessibility in the latter, should a repeat embolisation be necessary (9).   
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Exhaustive BAE involves the embolisation of pathological systemic vessels such as transpleural 
vessels, intercostal vessels, axillary artery branches, internal mammary arteries, branches of 
thyrocervical and costocervical trunks and the left gastric artery, and the inferior phrenic artery 
branches (9).   
Regardless of the etiology BAE is at best a palliative procedure (11, 12), to staunch the 
haemoptysis until definitive intervention is performed to prevent relapse.  For active PTB the 
long term management is effective medical therapy to reduce the local inflammatory 
environment and thus prevent recurrence.  For associated etiology, such as the presence of 
aspergilloma, surgical management to remove the site of pathological lung is needed to prevent 
recurrence as this is resistant to other therapies and is a cause of relapse in haemoptysis (25, 26). 
In case of chronic PTB medical therapy is the definitive management with BAE serving as a 
palliative procedure. In patients with sequelae of old and treated PTB who present with 
haemoptysis, BAE is effective in controlling haemoptysis.  Recurrence is an indicator for 
considering surgical management as even extensive re-embolisation has been shown to be non-
effective (2). 
Recurrence of haemoptysis may be the result of incomplete embolisation (36), recanalization of 
previously embolised vessels, collateral vessel revascularization of the region associated with 
progression of the disease (9, 12) especially in the setting of default of medical therapy (11).  
Early recurrence is usually due to incomplete embolisation while recurrence after 1 year is most 




While international studies report the presence of aspergilloma as the major cause of recurrence 
of haemoptysis following BAE (25, 26), a local study reports 4 reasons for an increased 
likelihood of recurrence of haemoptysis following BAE namely, ongoing haemoptysis beyond 7 
days after BAE, blood transfusion required during BAE, presence of aspergilloma and patients 
receiving treatment for active PTB at time of the procedure(27). 
 
1.9 Management Options and Protocols at IALCH 
Following admission and haemodynamic stabilization an HRCT Chest or diagnostic CXR was 
performed to identify source of bleeding and to localize sites of bleeding. 
If the patient is deemed a non surgical candidate by the cardiothoracic team, an emergency non 
exhaustive BAE was performed.  At IALCH the indications to opt for bronchial artery 
embolisation rather than surgery included patients that were HIV positive with CD4 < 400 
(unless the presentation was life threatening), non-localised or bilateral disease, non-operative 
clinical patient profile, or recent bout of massive hemoptysis in a patient stable enough for 
bronchial artery embolisation.  
This procedure may or may not be accompanied by embolisation of non-bronchial systemic 
vascular feeders. At this time, no limit was placed on the number of bronchial artery 






CHAPTER 2:  METHODS 
2.1   Study Design 
A retrospective analysis of clinical and radiological data was used to establish whether co-
infection of HIV and PTB (acute and sequelae) has an impact on the success rate of BAE 
procedure. 
The analytical component of the study aims to determine if co-infection adversely affected the 
outcome of the procedure (clinical and procedural).  It also aims to determine if CD4 level 
affects the outcome of the procedure. 
The descriptive component of the study aims to determine the cause for unsuccessful BAE 
studies in these patients. 
 
2.2   Study Participants 
IALCH is an 846 bed hospital of specialties in central Durban and serves as the draining hospital 
for all of Kwa Zulu Natal (KZN). The radiology service caters for all admitted patients. 
One hundred and ninety eight bronchial artery embolisation procedures were performed from 
January 2006 to 31 December 2007.   This study was performed on consecutive patients who 
underwent Bronchial Artery Embolisation (BAE) and who met the selection criteria.  The cohort 




The required sample size was calculated using a 95% confidence interval.  The significance level 
of the test was targeted at 0.05000.  The sample size required was 26 in one group and 42 in the 
other to achieve 81% power to detect a difference between the group proportions of -0.3000.  
The proportion in group one (HIV positive) is assumed to be 0.9000 under the null hypothesis 
and 0.6000 under the alternative hypothesis, the proportion in group two (the control group – 
HIV negative) is 0.9000.  The significance level actually achieved by this design is 0.0266.  The 
sample size of 107 patients (33 HIV negative, 74 HIV positive) is adequate. 
 
The selection criteria included: 
1. History of previous pulmonary tuberculosis, or microbiological or radiological diagnosis 
of active or sequelae pulmonary tuberculosis on HRCT or CXR. 
2. Clinician assessed need for BAE namely not a surgical candidate. 
3. Life threatening or massive haemoptysis accounted for by the diagnosis or complications 
of PTB. 
4. First and second attempts at embolisation only. 
 
Exclusion criteria included: 
1. Other cause of haemoptysis as identified clinically, radiologically or microbiologically.  
These included lung abscess, bronchiectasis without previous history of tuberculosis, 
carcinoma, cystic fibrosis, pneumonia, pulmonary interstitial fibrosis, pneumoconiosis, 
congenital cardiac and vascular abnormalities, aortobronchial fistula, aortic aneurysm, 
bronchial artery aneurysm or pulmonary artery aneurysm. 
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2. Minor haemoptysis. 
3. Third or subsequent BAE for the same diagnosis. 
4. HIV status unknown. 
 
The diagnosis of PTB was made as follows: Cases were included if they had a history of PTB 
(treated or otherwise).   If not, charts were searched for microbiological evidence of PTB in 
current sputum samples.  If this was negative, the chart was searched for radiographic features of 
active or previous tuberculous infection.  If this was not found, clinical data and clinical 
diagnosis of PTB was relied upon.  
Retrospective data capture to assess demographic, clinical (diagnosis and follow up) and 
laboratory parameters was performed and captured on an Excel document.   
Images captured were those that were documented on the Picture Archive and Communication 
System (PACS).  The images were analyzed by an independent radiologist who was provided 
with the images, the report from the performing radiologist, a checklist (annexure 2), and was 








2.3   HRCT Chest:  Procedure 
Scans were acquired on a Siemens Somatom Sensation 16 slice Computed Tomogram Scanner.  
Patients were positioned supine with arms above the head and the scan field extends from the 
sternal notch to the diaphragm. Scans of 1mm slice thickness with 10mm gap were acquired and 
reconstructed prospectively on a high (sharp) spatial frequency kernel for lung windows and on a 
medium smooth kernel for mediastinal windows.  
 
2.4   Bronchial artery embolisation: Procedure 
The procedure was performed on the Siemens Artis FA angiogram system and utilizes Digital 
Subtraction Angiography technique.  As with any interventional procedure there are risks and 
complications, that one needs to be aware of, before embarking on the procedure.  Normal 
precautions for preventing exposure to blood borne risks were followed. (Annexure 3) 
The procedure was performed by a registrar in Radiology under the guidance of a qualified 
Radiologist as part of their clinical training. Registrars rotating through the IALCH were 
involved in the procedures.  All registrars involved had successfully completed their Part 1 
examination in Diagnostic Radiology through the College of Medicine of South Africa (CMSA).  
The procedure is conducted as a sterile procedure and is initiated with routine pre-procedure 
assessments of pulse, blood pressure, oxymetry and a clinical neurological assessment. 
Access to the vasculature is via groin puncture of the right or left femoral artery using the 




A pan descending thoracic aorta arteriogram using a 110cm 5F pigtail catheter was then 
performed to detect the ostia of bronchial arteries and exclude anomalous origins of bronchial 
arteries or systemic vascular pathology (9).  30-40ml of non-ionic iodine based contrast via an 
injector at a rate of 12-15ml/second was injected and 2 views (posteroanterior and right anterior 
oblique) were obtained.   
Bronchial artery selection was undertaken even if the visualized bronchial arteries appeared 
angiographically normal on the panaortogram(9). These were selected using an appropriate 
catheter and guidewires.  Catheters available included the Headhunter, Cobra, Mickaelson, 
Maney, Sim 2 and Sidewinder in 4F and 5F.  For embolisation, only end hole catheters were 
used as this is mandatory to prevent non-target embolisation (9). The guidewire available was the 
5F standard J tip Emerald Guidewire. 
Hand injection of 2-5mls of undiluted non-ionic low osmolar iodine contrast (300mg Iodine/ 100 
milliliters) was used to obtain the bronchial artery arteriogram.  The bronchial arteries were 
assessed for pathology.  Sub-selection (if needed) was attempted using the same or smaller size 
catheters.  Co axial microcatheters were not available as none of the radiologists or registrars 
were trained in its use.  
Embolisation was performed with 2ml boluses of large embospheres (900-1200 micrometers) to 
which 8ml of contrast was added to improve visualization and to alert one to reflux of embolic 
material.  Frequent angiographic ‘runs’ were performed with 2 minute wait periods in-between 
injection of embolic material.  This was done to assess for progress of vessel occlusion, 
subjective degree of increase in vessel resistance, and presence of steal phenomenon when 
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possible contraindications may become evident as the distal vessel occludes.  The endpoint of 
embolisation was when there was stasis of contrast within the bronchial artery (9). 
Post embolisation clinical neurological assessment on table was done prior to transfer to ward. 
 
2.5  Laboratory Investigations 
At the discretion of the supervising clinician, microbiological samples were sent to the laboratory 
for microscopy and culture and blood samples were sent for HIV testing. 
2.5.1  Microbiology 
In those patients with no history of previous pulmonary tuberculosis, a positive microbiological 
test for the disease was interpreted as sufficient proof of infection.  As multiple factors were used 
to diagnose PTB infection for the study, the positive AFB or culture tests were included in the 
study but the negative tests were not excluded unless no other (clinical, radiological) evidence of 
active or old PTB was present.  Annexure 4 describes the local laboratory handling of a sputum 
sample for microscopy and culture. 
The sputum sample is initially decontaminated with alkali, neutralized with acid and centrifuged.  
The sediment is stained with Auramine and cultured routinely.  Mycobacterial growth indicator 
tube (MGIT) bottle is plated onto solid Middlebrook agar media for first & second line 
susceptibility testing (INH, Rifampicin, Streptomycin, Ofloxacin and Kanamycin).   
Positive MGIT bottles have a Ziehl-Neelson stain performed.  If these are ZN positive and 
cording is present then the sample most likely represents MTB.  If acid fast bacilli are present but 
no cording is noted on positive MGIT bottle, an MPT 64 Antigen test (immunochromatographic 
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rapid) is done. If negative, the report is sent out as Mycobacterium other than Tuberculosis 
(MOTT). 
Smear positive samples, positive cultures and positive immunochromatographic rapid tests are 
sent to  a molecular facility for line probe assay which determine whether the isolate is TB and 
determine susceptibility results for INH and Rifampicin.  If the line probe assay shows that it is 
resistant to INH and/or Rifampicin further drug susceptibility test is done. 
 
2.5.2  Virology 
The HIV screening assay used by the lab is the 4th generation Elisa.  It detects both HIV antigen 
and antibody and is run on the Roche Modular platform.  The confirmatory assay is a 3rd 
generation Elisa and detects HIV antibodies and is run on the Advia Centaur platform. 
An HIV diagnosis is only made if both tests are positive.  In the case of discrepant results an HIV 
PCR or Western Blot is performed on a separate sample.  
At the time of the procedure, the operator may or may not have been aware of the HIV status and 







2.6  Ethical Considerations 
Protocol (student number: 933481893) and Ethical (reference number: BE059/010) approval was 
obtained from the University of Kwa Zulu Natal’s Postgraduate and Research Office. (Appendix 
5 and 6 respectively) 
Permission to conduct the study at IALCH was obtained from Chief Executive Officer of 
IALCH.  (Appendix 7) 
The study is a retrospective analysis of data and images of the procedure and consent was not 
considered to be required. 
HIV and CD4 testing was conducted at the discretion of the Cardiothoracic clinician.  HRCT 
chest and testing of sputum for PTB was part of routine clinical workup of the patient.  No 
additional test was performed solely for this study. 
Confidentiality was respected throughout the data collection and will remain such.  Each case 
was assigned a numerical code and this code was used in the different aspects of data collection 
and image analysis prior to collation by the primary investigator alone.  
 
2.7  Data Capture and Analysis 
A pilot study was not performed.  Review of the electronic clinical records was performed and 
the relevant data captured by the primary investigator (Data capture form – annexure 8).  Review 
the HRCT and BAE was performed by an independent radiologist – Dr G Bydawell who has 
been trained as an interventional radiologist and is now employed in private practice in Durban. 
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The data was recorded onto an Excel spreadsheet and differences between the groups were 
analyzed using the Chi squared test, Fisher’s exact test or the Mann-Whitney test, as appropriate, 
using the SPSS programme.  A probability- value (p) of less than or equal to 0.05 was considered 
significant. 
 
2.8  Outcome measures 
2.8.1 HRCT  
Active PTB was suggested by the following radiological features on CXR and HRCT chest in 
the appropriate clinical setting: 
1. Presence of a secondary focus or tuberculoma or nodules.  The secondary focus may 
be infiltrative or consolidative and may cavitate.  Nodules may be miliary, 
centrilobular and acinar.  A nodule is a rounded or irregular opacity, well or poorly 
defined, measuring up to 3cm in diameter. Miliary pattern consists of profuse tiny, 
discrete, rounded pulmonary opacities that are uniform in size (3mm in diameter) and 
diffusely distributed throughout the lungs. Centrilobular nodules may be of soft-tissue 
or ground-glass attenuation, are ill defined and range in size from a few millimeters to 
a centimeter.  Tree-in bud opacities or centrilobular nodules with or without 
cavitation suggesting bronchogenic dissemination.  






Sequelae of PTB are suggested by the following radiological features on CXR and HRCT chest: 
1. Fibroarchitectural disortion (fibrotic bands, calcified nodules, atelectasis, 
emphysema, bronchiectasis and volume loss).  This may be accompanied by 
destruction of lung in the setting of history of previous PTB. 
2. Presence of cavitation and mycetoma in the setting of history of previous PTB. A 
cavity is an air-filled space, seen as a lucency or low attenuation area within an area 
of consolidation, a mass or a nodule.  
 
2.8.2 BAE 
Clinical outcome was considered successful if there was immediate cessation of haemoptysis or 
cessation of haemoptysis by discharge following embolisation in the absence of any other 
intervention. 
The radiological procedure was considered successful if there was successful identification of 
pathological vessels and embolisation was performed with success.  The radiological procedure 
was considered unsuccessful if embolisation was not undertaken. 
  
The radiological procedure was described as partial embolisation with clinical success if only 
some of the abnormal vessels were embolised and the clinical outcome was successful namely, 
cessation of massive haemoptysis. The radiological procedure was described as partial 
embolisation with clinical failure if only some of the abnormal vessels were embolised and the 
clinical outcome was unsuccessful namely, further definitive management was needed to staunch 
the haemoptysis.  This included sedation and medical therapy, repeat bronchial artery 
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embolisation procedure, surgery or readmission at a later date or if a serious complication such 
as non-target organ embolisation or death occurred. 
Angiographic findings to suggest pathological bronchial arteries are hypertrophic and tortuous 
bronchial arteries, neovascularity, hypervascularity, and bronchial artery shunting into 
pulmonary arteries or veins, extravasation of contrast media when injected into bronchial artery, 
bronchial artery aneurysm and non-bronchial systemic vascular abnormalities.   
Technical reasons for failure of BAE included: 
1. Inability to select the primary artery such as the bronchial artery 
2. Inability to sub-select specific divisions of the artery for safe embolisation 
3. Instability of catheter tip  
4. Reflux of the contrast media into the parent vessel 
5. Visualization of a contraindication such as a bronchio-pulmonary vein fistula, 
bronchio-pulmonary artery fistula, bronchio-visceral artery fistula or spinal artery 
6. No pathological vessel identified 
 
2.9  Clinical record  
The diagnosis and results of microbiological or virological test were retrospectively acquired 
from the patients chart.  The clinical outcome of the procedure and clinical follow up were 





CHAPTER 3:  RESULTS 
One hundred and ninety eight BAE studies were performed at IALCH in the period 1 January 
2006 to 31 December 2007. 
One hundred and seven (54%) cases were included in the study.  The remaining 91 cases were 
excluded from the study for reasons displayed in Table 1.  Some cases had more than one reason 
for exclusion.  The commonest reason for exclusion was the lack of HIV results – 53/91 (58.2%), 
followed by the presentation of minor rather than major haemoptysis – 42/91 (46.2%). 
Table 1: Excluded cases 
Reason for exclusion (n=91) Number of cases 
Study not found 10 
Minor haemoptysis  42 
HIV unknown 53 
Diagnosis other than PTB 2 









3.1  Patient Demographics 
3.1.1 Age and HIV status 
The age and HIV status of the included cases is displayed in figure 2.  The age of included cases 
ranged in age from 15 to 67, with an average age of 36.6 years.  The majority 37/107 (34.6%) of 
the patients were between 30 and 39 years old.   
For HIV positive patients the distribution of ages is nonparametric with a standard deviation of 
9.19 years.  The median age of patients who are HIV positive is 32 years.   The highest age in 
this category is 55, the lowest age is 20.  
For HIV negative patients the distribution of the ages is normal with a standard deviation of 
14.383 years.  The average age of patients who are HIV negative is 40.85 years.  The highest age 





























3.1.2  Gender and HIV status 
The gender distribution and HIV status is displayed in figure 3. There is no statistical 


























Figure 3:   Histogram of gender and HIV status 
 
3.1.3.   HIV Status and CD4 Levels 
Of the 107 included cases, 33 (30.8%) are HIV negative and 74 (59.8%) are HIV positive. The 
number in each category was adequate for the study. 
CD4 levels were known in 57/74 (77%) cases.  The distribution of the available data is non-
parametric.  The median level is 176. The highest level recorded is 768 and the lowest level 
recorded is 1.   Using a CD4 count of 200 as a cutoff point, the majority 35/74 (47.3%) of cases 






















Figure 4:  Histogram of available CD4 counts (n=57) 
 
3.1.4  Previous bronchial artery embolisations 
Cases with a history of 3 or more previous BAE were excluded from the study.  14 cases had a 
history of 2 or less previous BAE, 7 are HIV positive and 7 are HIV negative.  There is no 
correlation between the incidence of a history of previous bronchial artery embolisations (<=2) 










3.2 Diagnosis of Pulmonary Tuberculosis 
The cases were included if they had history, microbiological, radiological or clinical evidence of 
PTB.  Seventy one (66.4%) cases had a history of previous pulmonary tuberculosis.  Of the 
remaining 36, 17 were diagnosed microbiologically, 18 had radiological evidence of active or 
old pulmonary tuberculosis and one was diagnosed clinically. 
Some cases met more than one criterion for diagnosis.  The majority (94/4%) of cases showed 
radiographic evidence of active (101/106 cases) or old PTB (102/106 cases).  There was no 
significance to the correlation of HIV status and the presence of active or old PTB. (p values of 
0.664 and 1.000 respectively)  
Sixty one (57%) cases were referred with a diagnosis of PTB and were already on treatment.  
Twenty eight (26.2%) cases are sputum examination positive for AFB or culture positive for 
MTB.  Nine (8.4%) cases are multidrug resistant positive PTB (MDR) with the majority being 
HIV positive cases (7/9 – 77.8%).  Nineteen (17.8%) cases were diagnosed on clinical grounds.   
The distribution of method of diagnosis of PTB across HIV status is displayed in table 2.  There 











Table 2: Method of diagnosis of PTB correlated with HIV status 
Diagnosis Method HIV negative HIV Positive 
History of previous PTB (n=71; p=0.120) 18 53 
AFB positive (n=28; p=1.000) 9 19 
MDR (n=9; p=0.718) 2 7 
XR evidence of old or new PTB (n=101; p=0.664) 32 69 
Clinical (n=19; p=1.000) 6 13 
Referral diagnosis (n=61; p=0.292) 16 45 
 
3.3 Imaging Findings 
There were 93 HRCT chest studies and 13 CXR available for review and all are abnormal.  The 
correlation of imaging technique availability and HIV status is not significant (p = 1.000) and 
thus all imaging, findings regardless of whether they were identified on HRCT or CXR, were 
analyzed together.  (Table 3) 
Table 3:  Imaging investigation availability correlated with HIV status 
 HRCT CXR 
HIV positive (n=73) 64 9 
HIV negative (n=33) 29 4 
 
There is no correlation between the zones involved and the HIV status of the cases.  In 57 cases, 
all four zones were involved and this is not statistically relevant when correlated with HIV status.  
The findings in terms of zonal distribution and HIV status is displayed in table 4.  
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Table 4:  Zonal distribution of pathological changes on imaging 
 HIV Positive (n=73) 
 
HIV Negative (n=33) 
Right upper zone (n=93; p=0.784) 66 30 
Right lower zone (n=81; p=0.645) 57 24 
Left upper zone (n=94; p=0.496) 64 30 
Left lower zone (n=86; p=0.566) 59 27 
All zones involved (n=57; p=1.000) 39 18 
 
The most common feature reported on the imaging in both HIV positive and HIV negative cases 
is architectural distortion with no significance when compared with HIV status (p = 1.000) 
namely 95.6% and 97% respectively. 
Lymphadenopathy is present in 18.9% of HIV positive cases and 42.2% of HIV negative cases 
and is the only features of significance when comparing with HIV status (p = 0.017). The other 
features and their incidence are listed in table 5. 
There is no significant difference in findings when correlating HIV status and active disease 
(namely presence of acute infection, pleural effusion and lymphadenopathy) (p = 0.664) or when 
correlating HIV status and features of disease sequelae (namely presence of architectural 

























HIV positive (n=73) 69  13 14  70  33  
HIV negative (n=33) 32  4  14  32  13  
p value 0.664 0.576 0.017 1.000 0.676 
p value 0.664 1.000 
 
3.4 Outcome  
Clinical success of the procedure is defined as the cessation of the haemoptysis following the 
procedure during this admission.   
The procedure was considered successful as the sum of 2 categories namely, embolised and 
partial embolisation with clinical success.  The procedure was considered unsuccessful as the 
sum of 2 categories namely, not embolised or partial embolisation with clinical failure. The 
distribution of different values across partially embolised with clinical success and partially 
embolised with clinical failure are equally likely (actual p value = 0.146).  The distribution of 
different values of embolised and not embolised are equally likely (actual p value = 0.213).   
There is no statistical significance when correlating each category of procedural outcome with 
HIV status. (Table 9) 
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This means that embolised and partially embolised with clinical success can be collapsed into 
one category and that not embolised and partially embolised with clinical failure can be 
collapsed into another category without affecting the results of the study. 
3.4.1 Clinical versus procedural outcome 
There is a significant difference in success rates for procedure versus clinical success for the 
entire caseload (actual p = 0.008).  (Table 6)  This means that the terms clinical and procedural 
success cannot be viewed interchangeably. 
Table 6:  Comparing clinical and procedural outcome  
 Clinical success 
No (n=56) Yes (n=51) 
Procedural success (n=63) 15 48  
Procedural failure (n=44) 41 3 
 
Fifteen cases were considered procedurally successful but did not have the desired clinical 
outcome.  Of these, 3 are HIV negative and 12 are HIV positive.  There is no significance when 
comparing this data with HIV status (p=0.183).  (Table 7)  
Table 7: Comparing procedural and clinical success based on HIV status 




HIV negative (n=33) Clinical success 14 0 
Clinical failure 3 16 
HIV positive (n=74) Clinical success 34 3 
Clinical failure 12 25 
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No significance in the correlation of clinical outcome with Gender and HIV status is noted. 
Failed clinical outcome p = 0.394, successful clinical outcome p = 0.522. 
No significance in the correlation of procedural outcome with Gender and HIV status is noted. 
Failed procedural outcome p = 1.000, successful procedural outcome p = 1.000. 
 
3.4.2   Clinical outcome  
Fifty one (47.7%) cases were clinically successful.  Of this, 3 (5.9%) could not be accounted for 
by procedure success and may be the result of conservative and or medical management.  (Table 
7) All 3 are HIV positive.  Fifty six (52.3%) cases were clinically unsuccessful and required 
alternative management.  (Table 8) 
There is no significance to the correlation of clinical success and HIV status (p=0.469). 
There is no difference in likelihood of any of the clinical follow up noted for either HIV positive 









Table 8:  Clinical follow-up correlated with HIV Status 




Clinical success (n=51; p=0.469) 37 14 
Alternative therapy 
required 
Medical therapy (n=29; p=0.150) 17 12 
Repeat bronchial needed (n=10;p=0.721) 8 2 
Surgery needed (n=16; p=0.564) 10 6 
Death during admission (n=4; p=0.309) 4 0 
Readmission (n=22; p=0.251) 13 9 
Complication (n=4; p=1.000) 3 1 
 
3.4.3 Bronchial Artery Embolisation Outcome  
A total of 63 (58.9%) cases were classified as procedurally successful.  A total of 44 (41.1%) 
cases were classified as procedurally unsuccessful.  There is no statistical significance when 
correlating each category of procedural outcome or the 2 categories defined above, with HIV 
status. (Table 9) 
Table 9:  Procedure outcome and HIV status 
Procedure outcome  HIV negative HIV positive Total (p value) 
Embolised (n=53; p=1.962) 13 40 63 (1.069)   
Partial embolised and clinically successful (n=10; p=0.434) 4 6 
Not embolised (n=40; p=2.512) 16 24 44 (1.069) 




3.4.3.1 Selection and embolisation of vessels  
Two hundred and twelve vessels were selected and 106 were embolised. (Table 10)  Not all 
selected vessels would need to be embolised and therefore the two categories were not 
correlated. 
Table 10:  Incidence of vessel selection and embolisation  
 Selected (n=212) Embolised (n=106) 
Right bronchial artery  83 43 
Left  bronchial artery 51 25 
Intercostobronchial artery 36 25 
Internal mammary artery 36 11 
Intercostal artery 6 2 
 
There is no significance in the correlation of selection of any of the vessels (right bronchial 
artery, left bronchial artery, intercostobronchial artery, intercostals or internal mammary arteries) 
and HIV status.  
There is no significance in the correlation of embolisation of any of the vessels (right bronchial 
artery, left bronchial artery, intercostobronchial artery, intercostals or internal mammary arteries) 






Table 11: Correlating the incidence of selection and embolisation of vessels in procedure failure 
with HIV status 
 Selected Embolised 
HIV negative HIV positive HIV negative HIV positive 
Bronchial arteries  Right bronchial artery  
p value 
25  58  11 32 
0.863 0.482 
Left  bronchial artery 
p value 




9  27  6 19 
0.661 0.737 
Systemic arteries Internal mammary artery 
p value 
12  24  2 9 
0.731  1.000 
Intercostal artery 
p value 




3.4.3.2 Reasons for technical failure of the procedure and HIV status  
Four factors were significant when correlated with overall failure of the procedure regardless of 
HIV status.  These are ‘unable to select’ (p=0.007), ‘unable to subselect’ (p=0.015), ‘spinal 
feeder’ (p=0.006) and ‘no bleeder identified’ (p=0.010).   
There is no difference in likelihood of occurrence of any of the factors investigated when 






Table 12:  Reasons for failure to embolise correlated with HIV status 
 HIV negative  HIV positive  
Unable to select (n=11; p=0.503) 5  6  
Unable to subselect (n=10; p=0.144) 6  4  
Unable to engage securely (n=3; p=1.000) 1  2  
Reflux observed (n=0) 0 0  
Bronchio-pulmonary artery fistula (n=4; p=1.000) 1  3  
Bronchio-pulmonary vein fistula (n=8; p=1.000) 3  5  
Bronchio-visceral fistula (n=5; p=1.000) 2  3  
Spinal feeder identified (n=15; p=0.646) 6  9  
No bleeder identified (n=5; p=0.651) 1  4  
Other (n=1; p=1.000) 0 1 
 
 
3.4.4 CD4 Level 
Of the 74 HIV positive cases, the CD4 value was available in 57 (77.0%) cases only.  The 
distribution of the data is non parametric therefore the median level is used for comparative 
purposes.   The median CD4 level is 176.  The highest recorded CD4 level is 768 and the lowest 
recorded CD4 level is 1.  The following results apply to the available data. 
The total number of clinically successful cases is 25/57 (43.86%).  The CD4 level in the 2 
categories has no significance when correlated with clinical success (p=0.829).  (Table 13) 
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The total number of cases of procedural success is 35/57 (56.1%). The CD4 level in the 2 
categories has no significance when correlated with procedural success (p=0.266). (Table 13) 
 
Table 13: Correlating CD4 value and clinical and procedural success  
 Procedure successful  Total 





no 12 5 17 





no 8 7 15 
yes 0 11 11 
 
Thirty one cases have a CD4 level at or below 176.  14 (45.2%) cases are clinically successful.  
Seventeen (54.8%) are procedurally successful.  In 5 (16.1%) cases the procedure is considered 
successful but the patient did not have a good clinical outcome (p=0.002). 
Twenty six cases have a CD4 level above 176.  Fifteen (37.9%) cases are clinically successful.  
11 (42.3%) are procedurally successful.  In 7 (26.9%) cases the procedure is considered 
successful but the patient did not have a good clinical outcome (p=0.007). 
The likelihood of a procedure being successful with poor clinical outcome is significant for both 






3.4.5 Complications and Mortality 
Four patients died during the admission.  All are HIV positive.  Statistically this not significant 
(p=0.309).  One died during the BAE procedure. 
Three cases resulted in severe complications.  All patients are HIV positive.  Statistically there is 
no significance in the correlation of complications (minor and major) and HIV status (p=1.000). 
Case 1: Infarction of the vermis and bilateral cerebellum following embolisation of a 
common bronchial artery.  The patient became restless during the procedure and the 
procedure was abandoned.  Infarction was confirmed on MRI. 
Case 2: ‘Locked-in syndrome’ following embolisation of the pons and left thalamus after 
the embolisation of the left bronchial artery.  During embolisation, a bronchio-visceral 
fistula with the left subclavian artery was observed and flow into the left vertebral artery 
was seen.  Infarction was confirmed immediately after the procedure on MRI. 
Case 3:  Lower thoracic spinal cord and conus medullaris ischaemia following 
embolisation of an intercostobronchial artery.  This complication was not suspected at the 
time of the procedure.   An MRI was performed the following day and confirmed features 
of cord ischaemia.  
One case resulted in minor complication of dysphagia but no clinical follow up is recorded. The 





CHAPTER 4:   DISCUSSION  
This study of 107 cases is the second largest study to date (after Ramakantan Ravi et al) that 
specifically investigates the success of the BAE procedure where the clinical presentation of 
massive haemoptysis is the result of PTB (active or sequelae), comparing success rates with HIV 
status.  The study also addresses the rate of technical success of the procedure, compares it with 
the rate of clinical success and correlates these with HIV status.  By investigating technical 
events during the procedure the study aims to determine reasons for failed BAE.  It is a 
retrospective observational study and had no impact on the outcome or method of management 
of the cases.   
A local study by Corr et al (1998) in the same geographic region, investigated 87 patients 
retrospectively who presented with massive haemoptysis between 1997 and 1998 in order to 
determine the ‘efficacy of BAE in the treatment of major haemoptysis’.  The rate of procedural 
success demonstrated in this study was 88.5% with the remaining having failed for unspecified 
technical reasons.  A successful clinical outcome was noted in 66.5%.  Fifty eight percent of 
patients had evidence of active PTB.  The HIV rate was 32% and 75% of these patients were 
successfully managed with BAE (38).   
International studies (Brazil, Turkey, USA, Hong Kong, France and Japan) have investigated the 
role of BAE since Remy et al in 1973 to Chun et al in 2010.  Most have investigated the role of 
BAE without specifically addressing this etiology in the context of coinfection with HIV (1, 2, 
11, 12, 25, 26, 29-31, 37, 39, 40) and specifically addressing only the cases with a clinical 
presentation of massive and life threatening haemoptysis (1, 12, 37, 39, 40).   
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From the initial caseload of 198 cases, 53 were excluded because HIV status was not 
documented in the case notes.  This may be due to the fear of stigmatization, patients concern 
that they would be managed differently should the diagnosis of HIV be proven, or non disclosure 
of a known diagnosis to clinician at this referral centre.  None of the cases were assessed for 
evidence of immunosuppression due to other causes such as poor general health, poor nutrition, 
diabetes or concurrent disease. 
The dominance of  PTB as a cause for massive or life threatening haemoptysis in our setting is 
reflected in the exclusion of only 2 cases due to other causes (asthma and metastatic cancer). 
Many (66,4%) had a history of PTB and 57% were referred from another health care facility with 
diagnosis of active PTB and were on treatment at the time of referral.  Twenty eight sputum 
cases were smear or culture positive for AFB or MTB respectively.  Nine (32,1%) of these were 
also multidrug resistance.  A large proportion of cases showed radiological evidence of either 
active or old disease (94,4%).  Features of active disease investigated in this study (acute 
infection, pleural effusion or lymphadenopathy) are demonstrated in 95,3% cases and features of 
sequelae of previous PTB (architectural distortion or mycetoma) are demonstrated in 96,2% 
cases.  This reflects the endemic nature of the disease in our environment.  All methods of 







4.1  Outcome 
The study did not demonstrate a difference in likelihood of procedural or clinical failure based 
on HIV status.  This supports the findings of a local study where it was first suggested that HIV 
positive patients tolerate the procedure well (38).  This study confirms that they tolerate the 
procedure as well as HIV negative patients.   
Furthermore there is no statistical significance to the correlation of HIV status and the likelihood 
of procedural or clinical success at the 2 categories of CD4 levels assessed. The likelihood of a 
procedure being successful with poor clinical outcome is significant for both categories of CD4 
levels and further studies with larger case numbers is warranted to investigate further. 
 
4.2 Imaging findings  
4.2.1 High Resolution CT Scan 
IALCH is a tertiary/ quaternary hospital which receives referral of cases that can no longer be 
managed at a primary or secondary health care facility.  This means that cases of a more serious 
nature would be encountered in this study.  This may explain why there is no difference in the 
ability to detect imaging findings on either HRCT or CXR. 
Post primary tuberculosis characteristically has a specific zonal distribution (28) namely upper 
lobe apical and posterior segments and apical segment of lower lobe in immunocompetent 
patients.   In this study no specific zonal distribution was demonstrated in either HIV positive or 
negative cases with 57 (53.8%) cases demonstrating disease (old or active) in all 4 zones.  This 
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may be the result of the referral of more complicated cases to this hospital.  Further studies in a 
primary care facility may be warranted to investigate the role of each imaging method. 
The only feature of statistical significance in the imaging assessment is the presence of 
lymphadenopathy (LAP) found in 42.4% of HIV negative cases.  This is observed to be almost 
twice as likely compared with HIV positive patients.  The literature suggests that LAP is a 
reflection of the host immune response in primary TB rather than post primary PTB (26). One 
study has shown that LAP occurs more frequently with HIV positive patients on review of CXR 
(14).  LAP in HIV negative patients +who have post primary TB may be under-reported because 
the lymphadenopathy is small and more difficult to detect on CXR than on CT scan and this 
would warrant further research.  Studies have shown that the small LAP is better detected on CT 
chest than on CXR(41).  
The relatively lower prevalence of LAP may be as a result of the predominance of post primary 
TB in our adult population or due to the degree of general immunosuppression (not necessarily 
due to HIV).  It is technically more difficult to detect small LAP on HRCT compared with 
detection on contrast enhanced thicker slice CT chest.  A single radiologist assessed each 
imaging study and while this may introduce a bias based on the ability to detect the findings, it 
does also standardize the assessment. 
The described imaging pattern of PTB with HIV coinfection is not demonstrated in this study.  
The incidence of active and old disease is not significantly different between HIV positive and 
HIV negative cases which may be due to high prevalence of PTB in our environment.  None of 
the imaging features investigated are of statistical relevance when correlated with HIV status. 
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The incidence of mycetoma is equally likely in HIV positive and HIV negative cases and may be 
the result of immunosuppression due to poor general health. 
The endemic nature of PTB in our environment is reflected by radiological features of PTB 
sequelae in the majority of the cases.  Although the literature suggests that it is more difficult to 
detect active disease when there are features of previous disease on CXR and CT scans (26), 101 
cases demonstrated features of active infection.  The higher incidence of coinfection may have 
resulted in more complicated cases in our environment, thus making imaging features more 
obvious. 
Only 15.9% of cases demonstrated pleural effusion but the detection of pleural effusion in the 
setting of previous pleural and parenchymal disease is difficult. 
 
4.2.2 Bronchial artery embolisation 
BAE is an expensive, time consuming and ‘technically demanding procedure’(37) with 
significant risk to patient and operator.  When BAE is performed for PTB in the setting of HIV 
other risks to the operator and patient need to be taken into account.  These include blood and 
blood product exposure and exposure to aerosol PTB/ MDR PTB as the procedure is performed 
in a closed environment over prolonged periods in the presence of actively expectorating 
patients.   Immunosuppressed patients may have other significant concurrent disease that could 
impact on the handling of contrast by the patient. 
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As the procedures were performed by numerous operators the risk of long term radiation 
exposure to the operator is negligible.  No adverse incidents such as needlestick injuries or eye 
splashes were recorded.  
Three cases resulted in serious complications and 4 deaths were noted as a result of the 
procedure.  Non target embolisation dominated the major complications.  A minor complication 
of dysphagia was recorded but no clinical follow up is recorded.  No incidence of contrast 
reaction was noted. 
There is poor correlation between technical success of the procedure and the clinical outcome for 
the entire caseload.  Sixty three of 107 cases were considered procedurally successful but 15 
(23.8%) did not have a good clinical outcome.  The remaining 48 cases demonstrated both 
technical and clinical success.  The difference is significant (p=0.008) suggesting that technical 
success does not imply symptomatic resolution.   
The procedure demands good angiographic technique and persistence.  Forty four (41.1%) cases 
were considered procedurally unsuccessful.  The literature reports rates of technical failure from 
0 to 56.5% by Chun et al (25).  
The 4 factors (‘unable to select’, ‘unable to subselect’, ‘spinal feeder’ (p=0.006) and ‘no bleeder 
identified’) that are significant when correlated with overall failure of the procedure, regardless 
of HIV status, suggests that better training and equipment availability may improve overall 
procedural success.  None of the factors investigated were significant when correlated with HIV 
status. The ability to select and to embolise arteries (bronchial and visceral) was equally likely 
for both HIV positive and negative cases.   
53 
 
Eleven (25%) cases failed because the operator was unable to select a vessel. Reasons for this 
could include operator inexperience, severe architectural distortion resulting in anatomical 
remodeling, lack of vessel dilatation and hypertrophy or the presence of vascular thrombosis.   
Ten (22.7%) cases failed because of the inability to subselect a vessel and this may be due to 
operator inexperience, non-availability of specific catheters, microcatheters or guidewires.  
Vascular fistulae were identified in 17 (38.6%) cases and served as a contraindication to 
embolisation.  This would be more relevant if smaller embospheres are available but only large 
embospheres were available.  
Spinal feeders were identified in 15 (34.1%)  cases and this is not in keeping with the literature 
available, that quotes rates of approximately 11.5% (11).  The higher incidence of spinal feeders 
in this study may be the result of over-reporting, as review of the images suggest that proper 
confirmation was not undertaken. The decision not to embolise may be a reflection of operator 










CHAPTER 5:   CONCLUSION  
5.1   Projected study benefits 
The finding that clinical and procedural success cannot be viewed interchangeably addresses the 
limitations of the procedure technique at our centre and thus calls for greater training and 
formation of an interventional unit in order to optimize services.  In addition, this knowledge 
may be used to address both clinician and patient expectations and assist in obtaining informed 
consent. 
The finding that both clinical and procedural success is independent of HIV status reinforces the 
need to not discriminate against HIV positive patients for this method of management. 
Furthermore, there is no technical factor to account for a greater chance of procedure failure in 
HIV positive cases and this would allow for standardization of the procedure. The observed 
limitations of the technical aspects of BAE in our centre can be addressed and improved upon, so 
that the procedure may again be used to offer palliative benefit to patients in whom surgery is 
contraindicated.   Further studies are required to assess procedural and clinical outcome when 
sub-selection and super-selection is being practiced and the procedure technique is optimized. 
The study confirms that both CXR and HRCT chest were able to demonstrate the same features 
in order to determine suitability for BAE.  This is thought to be reflective of the severity of 
disease referred to IALCH.  In centers where HRCT is easily accessible, it is the ideal method 
for pre-embolisation investigation, but in centers of limited resources the CXR can be 
successfully used as a cost effective screening tool.   
The finding that lymphadenopathy is more likely in HIV negative patients (p=0.017) may serve 
as a predictor for the absence of HIV infection when a patient refuses to consent for such testing. 
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Regardless of this, the presence of lymphadenopathy should not be used as an excuse to ignore 
the universal precautions observed during angio-invasive procedures. 
The interpretative aspect of the study was performed by a single investigator thus limiting 
subjective variance in the interpretation of the CXR, HRCT chest and BAE. 
 
5.2   Study limitations and suggestions 
The procedure was performed by registrars at our centre at different stage of training, in the 
absence of a dedicated interventional unit, and the results may be a reflection of suboptimal skill. 
The acknowledgement of this should prompt one to improve training or establish a dedicated 
interventional unit.  Once the procedure is standardized and the technique improved, further 
studies are warranted. 
BAE is complex procedure and requires specific resources and thus cannot be performed at 
primary and secondary level health care facilities.  The patients included in the study are those 
that were referred to the specialist unit for management, and are likely to have more complicated 
disease and more obvious imaging findings.  This may affect the result of comparing CXR and 
HRCT for detection and assessment of the disease.  Furthermore the general health status of each 
case was not assessed and reasons for immunosuppression other than HIV infection were not 
taken into account.   
The high rate of PTB and HIV infection in our population and at this referral centre as well as 




The bias in the interpretation of the imaging findings and BAE may have been improved by 
double blinded reporting. 
 
5.3 Conclusion 
The study confirms the statement by Yoon et al in 2002 that ‘BAE is a technically demanding 
procedure and should always be performed by skilled interventional radiologists’ (13). 
HIV infection should not alter accessibility to BAE or affect the technical aspects of the 
procedure in a patient with massive haemoptysis. The knowledge of this may ease the concerns 


















Annexure 1:  Literature review summary 


































No success rate of 41/49 
‘Long term success of embolisation depends not 
only on the quality of arterial occlusion but also on 
the efficacy of the medical treatment.  The 






3 failure to 
select vessel 
68 PTB Life threatening 
haemoptysis 
No ‘BAE is an effective treatment for immediate control 
of life-threatening haemoptysis, allowing long-term 
control of bleeding in the majority of patients’ 
Ramakanta
n et al., 
1996 
140 no technical 
difficulties 
reported 
140 PTB  greater than 
300mL 
No almost complete control achieved in 102 patients 
‘patients with massive haemoptysis due to 
















No combination therapy of repeat BAE and or surgery 
as the results showed recurrent haemoptysis in 12-
21 % of cases 
‘the patients with Mycetoma suffered the highest 















No ‘BAE is a simple and life saving procedure and 
should be considered as the primary method of 
treatment in haemoptysis or as a preoperative 
method to stabilize the patient before surgery’ 
Corr 1998 87 
 
10 failed on 
technical 
grounds – not 
specified 






‘BAE is an effective treatment for major and 
massive haemoptysis in patients with pulmonary 
inflammatory disease who are not surgical 
candidates.  Patients who are HIV – positive are 
able to tolerate the procedure well’ 















life threatening  No success rate of 77% in 56 cases with long term 
control achieved in only 45% of cases beyond 3 
months 
‘BAE is an effective technique in the emergency 
treatment of life-threatening haemoptysis but shows 
that complications are not rare.  In view of the 
results we continue to favor the simplest and the 
quickest procedure, most likely to control 
haemoptysis at the first embolisation rather than 












4  no bleeder  
identified 






to close to 
great vessels 
68 PTB  12 massive No 82% short term effectiveness and 50% 
effectiveness with patients with recurrent 
haemoptysis 
‘BAE have been demonstrated to be useful in 
haemoptysis because of PTB’ 
Swanson 


































Active PTB 1 
massive No ‘our overall success rate in the control of bleeding 
immediately after the procedure was 97%’ 
‘BAE is a safe and effective means of controlling 
massive haemoptysis and should be regarded as 
the first-line treatment for this condition.’ 
Kim Yong 













Massive in 94 No 72.9% immediate control 
‘BAE with appropriate medical treatment should be 
sufficient for most patients with massive 
haemoptysis.  In patients with massive haemoptysis 
due to aspergilloma, however, elective surgery 















No success rates of 98.5% immediately and 90% at 1 
month 
‘BAE us a safe and effective palliative treatment 
alternative in moderate and massive haemoptysis’ 





Active PTB 5 
Old PTB 42 
Mycetoma 3 
120 mL median No ‘BAE was effective in a series with a sizable 
proportion of patients suffering from chronic 
recurrent haemoptysis, which is a common problem 
with a clinical significance akin to acute major 
bleeding.’ 
Chan 2009 251 
162 BAE 
 Inactive PTB 
62 
Active PTB 13 
Mycetoma 10 












Disease noted in: 
Right Upper zone  
Right Lower zone  
Left Upper zone  
Left Lower zone  
 
Disease features: 
Active disease  
Architectural distortion  
Pleural effusion  













Bronchial Artery Embolisation 
Selected vessels: 
Right bronchial artery  
Left bronchial artery  
Common bronchial artery  
Other: (specify)  
Subselection performed  
Embolisation of pathological vessels: 
Right bronchial artery  
Left bronchial artery  
Common bronchial artery  
Other: (specify)  
Failed embolisation cause: 
Unable to select  
Unable to subselect where required  
Unable to engage securely  
Reflux noted  
Bronchial-pulmonary artery fistula  
Bronchial pulmonary vein fistula  
Bronchial-visceral fistula  
Spinal feeder identified (before or 
during embolisation attempt) 
 
Other: (specify)  
60 
 
Annexure 3:  GUIDELINES: BASIC ELEMENTS OF UNIVERSAL PRECAUTIONS FOR THE 
PREVENTION OF HIV AND HBV INFECTION IN HEALTH CARE SETTINGS 
 
1. Body fluids should be handled with the same precautions as blood 
Cerebrospinal fluid, peritoneal fluid, pleural fluid, pericardial fluid, synovial fluid, amniotic fluid, semen, vaginal 
secretions, breast-milk, unfixed tissues and organs (including the placenta), any bloodstained body fluid, and saliva 
associated with dentistry should all be handled with the same precautions as blood. Body fluids such as urine, sweat 
and saliva (except in the context of dentistry) do not pose any known risk. 
 
2. Avoidance of sharp objects (sharps) 
• Recognize and avoid all potentially risky objects, not only needles and knives. Examples include towel clips, 
suction drain introducers and bone spicules. 
• Hollow needle-stick injuries account for almost all nosocomial infections recorded. 
• Never allow a sharp, especially a contaminated one, near fingers. For example, do not re-sheath used needles, use 
instruments to load and unload scalpel blades. 
• Take personal responsibility for the immediate safe disposal of all sharps used. The safe Disposal of sharps 
requires further specialized precautions. 
• Never hand a sharp to another person. Use an agreed neutral area where the sharp is placed and then picked up. 
The use of magnetic pads assists with this in the operating room. 
• Never pick up a sharp without looking at it. 
• Never put a sharp down except in an agreed neutral area. 
• Use the safest sharp that will do the job. For example, knives and needles for skin only, scissors and round-nosed 
needles for tissues. 
• Never feel for a needle point (or other sharp object) with the fingers. 
• Never put fingers in areas or wounds where a sharp is being used. 
• Do not shave patients pre-operatively or pre-delivery unless it is essential for the procedure. 
• Avoid the use of wire sutures if possible. 
• Use heavy-duty gloves (ring link or similar) in hazardous situations (broken bones, sharp foreign bodies). 
 
3. Avoidance of skin or mucous membrane contamination 
The following three risks are identified: 
a) Contamination of hands with body fluids 
b) Spillage on the HCW’s body 
c) Spray / aerosol to eyes and face 
 
Hand protection: 
• Only have direct contact with a patient and potential fomites (e.g. soiled linen) if non-intact skin on the hands 
(eg.cuts, eczema) can be completely isolated by impermeable adhesive tape. 
• Wear appropriate quality gloves: 
(i)   Every HCW handling blood/body fluid must use latex gloves 
(ii )Remove torn gloves immediately and wash away contamination; and 
(iii) Double-gloving reduces skin contamination during operations by 80% and may reduce the risk associated with 
sharp injury. 
 
Blood/body fluid spillage: 
• Use plastic aprons and impermeable boots where risk of spillage exists. 
• Ensure that spillage is immediately cleaned according to the guidelines in 4.5. 
• All blood and other specimens must be in containers with non-leaking stoppers or lids, and be placed in sealed 
plastic bags. 
• All unfixed tissues and organs (including placentas) must be placed in sealed plastic bags prior to incineration. 
 
Spray / aerosol precautions: 
• Use face eye protection (face-shields, eye goggles) where risk exists. 




4. Decontamination from blood and other body fluids 
• Skin – wash with soap and water at once. 
• Mouth and eyes – wash copiously with water. 
• Skin puncture – allow to bleed. 
 
5. Cleaning / disinfecting / sterilizing 
a) Disinfecting / sterilizing 
Moist heat (autoclaving) and dry heat (160° for 1 hour) readily destroy HIV. HIV is very sensitive and is destroyed 
by boiling for 5 minutes. A wide range of disinfectants may be used (see below). Thorough washing before 
disinfection or sterilization is essential for all equipment. Gloves and plastic aprons should be worn for this 
procedure. 
 
b)       Suitable disinfectants 
• Glutaraldehyde – 2% x 1 hour. 
• Hypochlorite solutions – 2000 parts per million (ppm) for general cleaning. 10 000 ppm x 30 minutes soaking 
blood-contaminated material. 
• Ethyl alcohol – 70% V/V x 1 hour. 
• Isopropanol – 70% V/V x 1 hour. 
• Iodine – 1% x 30 minutes. Inactivation of HIV occurs after 5 minute’s exposure to most of these agents. The 
longer exposure time given here accommodates the possible presence of other pathogens and the time required to 
destroy these pathogens, e.g. HBV. 
 
c)       Equipment 
Wear gloves when handling equipment contaminated by blood or body fluids. Bloodstained equipment must be 
wiped as clean as possible with paper towels, which must be discarded after use. Wipe the item with a hypochlorite 
solution (if suitable) and send it for the usual sterilization. If such cleaning is not possible, place the item in a sealed 
and labeled clear plastic bag. Protect sharp instruments adequately. 
 
d)        Linen 
Only handle bloodstained linen with gloved hands. If at all possible, contaminated linen should be placed directly in 
an appropriately sealed and labeled plastic bag from whence it should be tipped directly into a coldwater sluice or 
washing machine. If this is not possible the following steps should be taken: 
• Wipe off as much blood as possible. 
• Soak the bloodstained area in a bucket containing 10 000 ppm available hypochlorite for at least 30 minutes. 
• Send the linen for the usual laundering (hot water 65-70°C for 5 minutes). 
 
e)        Body fluid spillage: 
Wear gloves and remove the spillage with paper towels. Immediately discard the soiled paper towels into an 
appropriate bag for incineration. Once the area is largely free of organic material from the spillage, pour disinfectant 
containing 2 000 ppm available hypochlorite over the area and allow it to stand for at least 15 minutes. Use paper 
towels to wipe the area clean and dry. 
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Annexure 4:  Microbiology Handling of Sputum Sample 
Step 1: DECONTAMINATION OF SPECIMEN  
 
The NALC /NAOH solution dissolves mucus and cellular material thereby releasing mycobacteria and 
killing contaminating bacteria. 
Equal volumes of Nalc working solution is added to each specimen. NB For  stools,  neat  NAOH is  
added  and  CSF’s and  sterile fluids, half the  volume  of  Nalc working  solution  is  added. 
This is vortexed for 15 seconds, mixed and vortexed for further 15 seconds so that the specimens appear 
liquefied. (For those specimens still appearing viscous, 1ml NALC powder must be added and the 
specimen vortexed well.) 
The specimen is then left standing for 15 minutes - 20 minutes. After 20 minutes, buffer is added to 
neutralize the specimen. The specimen is inverted to mix. Specimens are centrifuged at 3000g for 15 
minutes. 
 
Step 2: MICROSCOPY 
 
A slide is prepared from the sediment for Auramine smears, which is a fluorescent stain 
Refer to National TB guidelines for reporting of sputum results 
Positive Auramine samples will sent to molecular facility for line probe assay which will determine 
whether the isolate is TB & also will give a susceptibility result for INH &Rifampicin. 
 
Step 3: CULTURE 
 
A culture is prepared from each sediment. 
15 Drops of decontaminated specimen (0.5ml) are inoculated into labeled MGIT media using a sterile 
glass Pasteur pipette. 
The MGIT tube is mixed and then loaded onto the BACTEC 960 instrument. - Automated 
MGIT=Mycobacterial growth indicator tube 
Instrument will flag positive usually 7-14 days after bottle loaded into machine 
Positive MGIT bottles have a Ziehl-Neelson done on them – if ZN positive & cording present-most likely 
MTB.  
MGIT bottle sent to molecular facility for line probe assay which will determine whether the isolate is TB 
& also will give a susceptibility result for INH &Rifampicin. 
If AFB present but no cording on positive MGIT bottle, an MPT 64 Antigen test 
(immunochromatographic-like pregnancy test –rapid) is done. If positive, MGIT bottle goes for line probe 
assay. If negative, specimen sent out as MOTT. 
If line probe assay shows that it is susceptible to INH &Rifampicin, no further drug susceptibility test will 
be done. 
If line probe assay shows that it is resistant to INH &/or Rifampicin, drug susceptibility test will be done. 
MGIT bottle will be plated onto solid Middlebrook agar media for 1st& second line susceptibility testing 









































Annexure 8:  Data Capture Form 
 
Data Collection Sheet    Patient Name: ….……. …………………........... 
BAE Study     KZ Number: …...………………………………. 
      Sex: …………… Age: ...……………….. 
Date of admission: ……………………. 
Date of discharge: …………………….. 
 
BAE:  Ω Emergency:   






Haemoptysis:     Pulmonary Tuberculosis: 
 Minor      Referral hospital diagnosis  
 Massive      On clinical assessment 
 Clinically life threatening 
        On microbiological assessment 
Previous BAE:       AFB 
 No       Culture 
 Yes: ……………………..     Resistance: ………………… 
       On CXR or CT 
HIV Status:      Previous PTB 
 Positive      Dates: ………………………... 
  CD4: …………….       
 Negative          
 Unknown  
        
 
 
Successful     Failed 
 
 Immediate     on this admission 
 By discharge     required surgery 
       Readmission 
       Death 
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